文献速递白血病

长春新碱和地塞米松脉冲联合维持治疗在儿童急性淋巴细胞白血病中的应用(GD-ALL-2008):一项开放标签、多中心、随机、III期临床试验

Vincristine and dexamethasone pulses in addition to maintenance therapy among pediatric acute lymphoblastic leukemia (GD-ALL-2008): An open-label, multicentre, randomized, phase III clinical trial.
PubMed 文献 · Am J Hematol · 2023-03-17

该开放标签、多中心、随机III期临床试验在广东省九大医疗中心开展,比较常规维持治疗与加用长春新碱/地塞米松脉冲治疗儿童急性淋巴细胞白血病的疗效与安全性。标准风险和中危组治疗组10年无事件生存率非劣于对照组,而高危组治疗组10年无事件生存率显著获益;高危组治疗组药物性肝损伤和3级化疗所致贫血发生率较低,但化疗所致血小板减少症总患病率较高。

要点

  • 高危组加用长春新碱/地塞米松脉冲后10年无事件生存率显著优于对照组。
  • 标准风险和中危组治疗组10年无事件生存率非劣于对照组。
  • 高危组治疗组药物性肝损伤和3级化疗所致贫血发生率低于对照组,但血小板减少症总患病率较高。

核心结论

  • 高危儿童急性淋巴细胞白血病适合在维持期加用长春新碱/地塞米松脉冲以获得优异结局,而标准至中危患者可免除脉冲治疗。

研究设计与样本

  • 开放标签、多中心、随机、III期临床试验,在广东省九大医疗中心开展,对照组384例接受常规维持治疗,治疗组375例接受长春新碱/地塞米松脉冲联合维持治疗。

主要发现

  • 标准风险队列10年无事件生存率对照组为82.6%(95%CI:75.9-89.9),治疗组为80.7%(95%CI:74-88.1),非劣效性P=0.0002。
  • 中危患者10年无事件生存率对照组为73.6%(95%CI:67.6-80),治疗组为77.6%(95%CI:71.8-83.9),非劣效性P=0.005。
  • 高危队列10年无事件生存率对照组为61.1%(95%CI:47.7-78.2),治疗组为72.6%(95%CI:55.6-94.7),P=0.026;10年总生存率对照组为73.8%(95%CI:61.6-88.4),治疗组为87.9%(95%CI:579.2-97.5),P=0.068。
  • 高危队列治疗组药物性肝损伤总发生率和3级化疗所致贫血发生率均低于对照组(55.6% vs 100%,P=0.033;37.5% vs 60%,P=0.036)。
  • 高危队列治疗组化疗所致血小板减少症总患病率高于对照组(88.9% vs 40%,P=0.027)。

临床怎么用

  • 作者认为高危儿童急性淋巴细胞白血病适合在维持期加用长春新碱/地塞米松脉冲,而标准至中危患者可免除脉冲治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The efficacy and safety on the addition of vincristine (VCR) and dexamethasone (DEX) pulses to maintenance therapy among childhood acute lymphoblastic leukemia (ALL) remain uncertain. Herein, we perform an open-label, multicentre, randomized, phase III clinical trial that was conducted at nine major medical centers in Guangdong Province, China. Patients were randomly assigned either the conventional maintenance therapy (control group, n = 384) or the VCR/DEX pulse (treatment group, n = 375). When limited to the SR cohort, 10-year EFS was 82.6% (95% CI: 75.9-89.9) in the control group and 80.7% (95% CI: 74-88.1) in the treatment group (pnon-inferiority = .0002). Similarly, patients with IR also demonstrated non-inferiority of the treatment group to the control group in terms of 10-year EFS (73.6% [95% CI: 67.6-80] vs. 77.6% [95% CI: 71.8-83.9]; pnon-inferiority = .005). Among the HR cohort, compared with the control group, patients in the treatment group experienced a significant benefit in terms of 10-year EFS (61.1% [95% CI: 47.7-78.2] vs. 72.6% [95% CI: 55.6-94.7], p = .026) and a trend toward higher 10-year OS (73.8% [95% CI: 61.6-88.4] vs. 87.9% [95% CI: 579.2-97.5], p = .068). In the HR cohort, the total rate of drug-induced liver injury and Grade 3 chemotherapy-induced anemia were both lower for patients in the treatment group than in the control group (55.6% vs. 100%, p = .033; 37.5% vs. 60%, p = .036). Conversely, the total prevalence of chemotherapy-induced thrombocytopenia was higher for patients in the treatment group than in the control group (88.9% vs. 40%, p = .027). Pediatric acute lymphoblastic leukemia with high risk is suitable to VCR/DEX pulse during maintenance phase for the excellent outcome, while the standard-to-intermediate-risk patients could eliminate the pulses.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Qiu KY, Wang JY, Huang LB, et al. Vincristine and dexamethasone pulses in addition to maintenance therapy among pediatric acute lymphoblastic leukemia (GD-ALL-2008): An open-label, multicentre, randomized, phase III clinical trial. Am J Hematol. 2023. PMID: 36877527. doi:10.1002/ajh.26910

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。